|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
NovaBay Pharmaceuticals, Inc. Co-Authors Novel Study Demonstrating Chemical Impact of N-Chlorotaurine and NVC-422 on Bacterial Toxins
9/13/2012 9:38:35 AM
EMERYVILLE, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE-MKT:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of infections, announces data supporting the mechanism of action for its lead Aganocide compound, NVC-422, against toxins secreted by bacteria such as Escherichia coli (E. coli). The data was presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, on September 12, 2012 in a poster that featured a collaborative study with the Innsbruck Medical University.
|
|
|
|
|
|
|
|
|
|
|